xmd8 92 for in vivo (MedChemExpress)
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
93
Structured Review
MedChemExpress
xmd8 92 for in vivo
Xmd8 92 For In Vivo, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/xmd8 92 for in vivo/product/MedChemExpress
Average 93 stars, based on 23 article reviews
Xmd8 92 For In Vivo, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/xmd8 92 for in vivo/product/MedChemExpress
Average 93 stars, based on 23 article reviews
xmd8 92 for in vivo - by Bioz Stars,
2026-02
93/100 stars
Images
1) Product Images from "ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer"
Article Title: ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer
Journal: EMBO Molecular Medicine
doi: 10.1038/s44321-024-00138-7
Figure Legend Snippet: ( A ) Percentage of proliferation inhibition of A549, A427 and H460 cell lines treated with increasing doses of XMD8-92 or Seliciclib or in combination (top) 48 h after treatment and representative crystal violet-stained cells 72 h after drug treatment (bottom). The combination index (CI) showing the synergistic effect of combination of the 2 drugs is indicated; n = 3. ( B – D ) Relative quantification of Annexin V (AV) + Annexin V/PI (AV/PI)-positive cells by flow cytometry; n = 4 ( B ), colony forming capacity; n = 3 ( C ) and percentage of cell migration; n = 10 ( D ) of A549 cells treated with 10 µM XMD8-92 or Seliciclib or in combination, except for the colony formation assay in which cells were treated with 5 µM of each drug. ( E ) Immunoblot analysis of the indicated targets in A549 cells treated with the indicated doses of Seliciclib or XMD8-92 or in combination for 24 h. ( F ) Immunoblot analysis of the indicated targets in A549 cells treated with 10 µM XMD8-92 or 10 µM Seliciclib or in combination for 24 h. ( G ) Immunoblot analysis for the indicated targets in A549 cells transduced with shRNA control (pLKO.1 hygro + Tet-pLKO-puro) or a shRNA against CDK5 (Tet-pLKO-puro-shCDK5 + pLKO.1 hygro), or a shRNA against ERK5 (pLKO.1 hygro-shERK5 + Tet-pLKO-puro) or in combination (Tet-pLKO-puro-shCDK5 + pLKO.1 hygro-shERK5). After transduction and selection, cells were harvested for protein extraction 72 h after doxycycline (1 μg/mL) induction. ( H , I ) Relative cell number ( H ) and Annexin V (AV) + Annexin V/PI (AV/PI)-positive cell quantification by flow cytometry ( I ) in A549 cells treated as in ( G ) 72 h after doxycycline (1 μg/mL) induction; n = 3. Graphical data are mean ± SD. Statistical analyses were done using one-way ANOVA; n , number of biologically independent samples. .
Techniques Used: Inhibition, Staining, Flow Cytometry, Migration, Colony Assay, Western Blot, Transduction, shRNA, Control, Selection, Protein Extraction
Figure Legend Snippet: Relative quantification of cell death by flow cytometry analysis of Annexin V-Atto 633 (AV) + Annexin V/PI (AV/PI)-positive (left) and colony number (right) of A427 cells treated with XMD8-92 or Seliciclib (10 µM for apoptosis assay and 2.5 µM for colony formation each, respectively) alone or in combination; n = 3. Graphical data are mean ± SD. Statistical analyses were done using one-way ANOVA; n , number of biologically independent samples.
Techniques Used: Flow Cytometry, Apoptosis Assay
Figure Legend Snippet: ( A ) Representative scheme of the in vivo experiment workflow. ( B ) Representative hematoxylin & eosin (H&E) staining (left) and quantification of the average tumor size (right) of lung tissue from LSL-Kras G12D/WT ;p53 flox/flox mice 10 weeks after Cre induction and after 2 weeks of treatment with vehicle, XMD8-92 (50 mg/Kg), Seliciclib (50 mg/Kg) or combination. Scale bar: 1 mm; n mice/group: 6, 3, 4, 4. Graphical data are ± SEM. ( C ) Representative images of immunohistochemistry against Ki67 (left) and quantification of Ki67-positive cells (right) in lung tissue from LSL-Kras G12D/WT ;p53 flox/flox mice, treated as in ( B ). Scale bar: 100 μm; n mice/group: 3, 3, 4, 4. Graphical data are mean ± SD. ( D ) Tunel-positive cell quantification in lung tissue from LSL-Kras G12D/WT ;p53 flox/flox mice, treated as in ( B ); n mice/group: 4, 3, 4, 4. Graphical data are mean ± SD. Statistical analyses were done using one-way ANOVA; n , number of biologically independent samples. .
Techniques Used: In Vivo, Staining, Immunohistochemistry, TUNEL Assay
Figure Legend Snippet: Body weight of Kras G12D/WT ;p53 flox/flox mice treated with vehicle or XMD8-92 or Seliciclib or combination of XMD8-92 and Seliciclib for 2 weeks.
Techniques Used:
Figure Legend Snippet: ( A ) Hierarchical clustering (Pearson Correlation, average linkage) of genes with standard deviation at top 5% showing a clear separation between A549 cells treated with DMSO (Control) or XMD8-92 or Seliciclib or combination of the two drugs (10 µM each) for 12 h; n = 3. ( B ) Dotplot showing the results of KEGG pathway enrichment analysis of genes that are activated or suppressed in A549 treated with XMD8-92 and Seliciclib in combination (10 µM). ( C ) Immunoblot analysis of the indicated targets in A549 cells treated for 12 h with XMD8-92 and Seliciclib (10 µM for each drug) alone or in combination. ( D ) Quantification of DHR (ROS marker, green) (left) and representative flow cytometry histogram (right) of A549 cells treated as in ( C ); n = 3. ( E ) Quantification of DHR (ROS marker, green) in A549 cells treated with the combination of XMD8-92 and Seliciclib (10 µM) or VS-4718 (5 µM) in the presence or absence of the SOD mimetic, MnTMPyp (25 µM); n = 3. ( F ) Immunoblot analysis of the indicated targets in A549 cell line treated as in ( E ) except VS-4718: 2.5 µM. ( G ) Relative cell number (top) and representative crystal violet images of A549 cell line treated as in ( F ) for 96 h; n = 3. Graphical data are mean ± SD. Statistical analyses were done using one-way ANOVA; n , number of biologically independent samples. .
Techniques Used: Standard Deviation, Control, Western Blot, Marker, Flow Cytometry
Figure Legend Snippet: ( A ) Quantification of DHR (ROS marker, green) in A549 cells treated with PF-562271 (10 µM) in the presence or absence of the SOD mimetic, MnTMPyp (25 µM); n = 3. Graphical data are mean ± SD. Statistical analyses were done using one-way ANOVA; n , number of biologically independent samples. ( B ) Immunoblot analysis for the indicated targets in A549 cells line, treated with DMSO (control) or with a combination of XMD8-92 and Seliciclib (10 µM) or PF-562271 (5 µM) in the presence or absence of the SOD mimetic, MnTMPyp (25 µM). ( C ) Metascape-derived analysis of the functional categories associated to the 5 clusters from main Fig. . Enriched terms were filtered based on the enrichment score and accumulative hypergeometric P values ( P < 0.05). Remaining significant terms were then hierarchically clustered into a tree based on Kappa-statistical similarities among their gene memberships. Then 0.3 kappa score was applied as the threshold to cast the tree into term clusters.
Techniques Used: Marker, Western Blot, Control, Derivative Assay, Functional Assay
Figure Legend Snippet: ( A ) Representative bright-field microscopy images of parental vehicle-treated A549 cells (left), VS-4718 tolerant cells (VS4718-T, middle) and VS4718-T upon withdrawal of the drug for 48 h (right). To obtain the VS-4718 tolerant (VS4718-T) cells, parental cells were treated with increasing doses of VS-4718 for 4 weeks and were after that maintained in 2.5 μM of VS-4718. Scale bars: 100 μm. ( B ) Percentage of proliferation inhibition of parental and VS4718-T A549 cells treated with increasing doses of VS-4718. Cell proliferation was determined 72 h post-treatment; n = 3. ( C ) Hierarchical clustering (Pearson Correlation, average linkage) of genes with standard deviation at top 5% showing a clear separation between A549 cells treated with VS-4718 (2.5 µM) for 12 h (acute) or rendered VS-4718 tolerant as described in ( A ); n = 3. ( D ) Analysis of the TRRUST module of Metascape showing that the genes of cluster 5 are identified as transcription factor targets (colored, left) and STRING database analysis showing the possible interaction between the different transcription factors (right). ( E ) Heatmap showing the expression profile of epithelial (KRT8,18) and mesenchymal markers of A549 cells treated as in ( C ). ( F ) Immunoblot for the indicated targets in A549 cells treated as in ( A ). The VS4718-T cells were maintained with 2.5 μM VS-4718. ( G ) Immunoblot for the indicated targets in A549 cells treated as in ( A ) and maintained at 2.5 μM. ( H ) Real-time PCR showing relative mRNA levels of ERK5 in A549 cells treated as in ( C ); n = 3. ( I ) Immunoblot for the indicated targets in A549 parental, VS4718-T and VS4718-T treated with XMD8-92 (10 μM). Heatmaps in ( C , E ) display a relative color scheme across samples that uses the minimum and maximum values in each row to convert the values into a scale ranging from 0 to 1. Graphical data are mean ± SD. Statistical analyses were done using one-way ANOVA; n , number of biologically independent samples. .
Techniques Used: Microscopy, Inhibition, Standard Deviation, Expressing, Western Blot, Real-time Polymerase Chain Reaction
Figure Legend Snippet: Body weight of Kras G12D/WT ;p53 flox/flox mice treated with vehicle or VS-4718 (FAKi) or a combination of VS-4718 and XMD8-92 (FAKi + ERK5i) for 2 weeks.
Techniques Used:
Figure Legend Snippet: Reagents and tools table
Techniques Used: Recombinant, Plasmid Preparation, Sequencing, shRNA, Reverse Transcription Polymerase Chain Reaction, Transfection, Western Blot, In Vitro, In Vivo, TUNEL Assay, Software